In the ever-evolving field of diabetes management, glucagon-like peptide-1 receptor agonists have emerged as a transformative therapeutic class. Among these, retaglutide, retatrutide, and trizepatide represent novel https://prestonhvdq964747.estate-blog.com/38008762/novel-glp-1-receptor-agonists-retaglutide-retatrutide-and-trizepatide